Michael R. Jirousek
Geen lopende functies
Profiel
Michael R.
Jirousek was the founder of Astria Therapeutics, Inc. (founded in 2008) where he held the title of Chief Scientific Officer from 2008 to 2015.
He is also the founder of Pfizer (La Jolla).
Jirousek's former jobs include Senior Director & Head-Diabetes Therapeutic Area at Pfizer Inc. (2001-2006), Head-Metabolic Department at Abbott Laboratories (1998-2001), and Program Leader & Scientist at Eli Lilly & Co. (1993-1998).
He was also Head-Research at Sirtris Pharmaceuticals, Inc. (2006-2011).
Jirousek earned a doctorate from Case Western Reserve University and an undergraduate degree from Kent State University (Ohio).
Eerdere bekende functies van Michael R. Jirousek
Bedrijven | Functie | Einde |
---|---|---|
ASTRIA THERAPEUTICS, INC. | Founder | 01-10-2015 |
PFIZER, INC. | Director/Board Member | - |
ABBOTT LABORATORIES | Corporate Officer/Principal | 01-01-2001 |
ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
Pfizer (La Jolla)
Pfizer (La Jolla) Miscellaneous Commercial ServicesCommercial Services Part of Pfizer Inc., Pfizer (La Jolla) is a private company that provides research services. The company is based in San Diego, CA. The company was founded by Michael R. Jirousek. | Founder | 01-01-2006 |
Opleiding van Michael R. Jirousek
Case Western Reserve University | Doctorate Degree |
Kent State University (Ohio) | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 4 |
---|---|
ABBOTT LABORATORIES | Health Technology |
ELI LILLY AND COMPANY | Health Technology |
PFIZER, INC. | Health Technology |
ASTRIA THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | Health Technology |
Pfizer (La Jolla)
Pfizer (La Jolla) Miscellaneous Commercial ServicesCommercial Services Part of Pfizer Inc., Pfizer (La Jolla) is a private company that provides research services. The company is based in San Diego, CA. The company was founded by Michael R. Jirousek. | Commercial Services |